10-K/A: TherapeuticsMD Files Amended 10-K to Include Omitted Information on Directors, Executive Pay, and Governance

TherapeuticsMD files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

Summary

• TherapeuticsMD, Inc. filed Amendment No. 1 on Form 10-K/A to its original Form 10-K for the fiscal year ended December 31, 2024.
• The amendment includes information required by Items 10, 11, 12, 13, and 14 of Part III of Form 10-K, which were initially omitted.
• The company did not expect to file its definitive proxy statement within 120 days of the fiscal year-end, necessitating this amendment.
• The filing includes new certifications from the principal executive officer and principal financial officer.
• The amendment does not include new financial statements or amend disclosures related to Items 307 and 308 of Regulation S-K.
• The document details information about the company's directors, executive officers, corporate governance practices, and executive compensation.
• As of April 18, 2025, TherapeuticsMD had 11,574,362 shares of common stock outstanding.
• The aggregate market value of voting and non-voting common equity held by non-affiliates as of June 30, 2024, was $13,408,634.
• The company's common stock is listed on the Nasdaq Stock Market LLC under the symbol TXMD.
• Berkowitz Pollack Brant, Advisors + CPAs served as the company's auditor.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document is a regulatory filing providing factual information. The need for an amendment suggests a minor negative, but the inclusion of governance and compensation details is standard practice.

Positives

• The company has a majority of independent directors, as required by Nasdaq rules.
• The Board of Directors has adopted charters for the Audit and Compensation Committees.
• The company has a compensation recovery (clawback) policy in place.
• The company has an insider trading policy and an anti-hedging and anti-pledging policy.
• The company encourages directors to attend the annual meeting of stockholders.

Negatives

• The company had to file an amendment to its 10-K to include previously omitted information, indicating a potential lapse in internal controls or oversight.
• The company does not expect to file its definitive proxy statement within 120 days of the fiscal year-end.

Risks

• The company faces operational, economic, financial, legal, regulatory, and competitive risks.
• The company's compensation policies and practices may have risks in attracting, retaining, and motivating valued employees.
• The company's business is subject to cybersecurity and information technology risks.

Future Outlook

No specific forward-looking statements or guidance are provided in this document.

Industry Context

This announcement is a standard regulatory filing update, providing transparency on the company's leadership, governance, and compensation practices, which is crucial for investor confidence in the pharmaceutical industry.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and committee chair retainers, is generally in line with industry standards for similarly sized companies.
• The executive compensation packages, including base salary and potential bonus, are typical for executive roles in the pharmaceutical industry, but the specific amounts should be benchmarked against peer companies of similar market capitalization and stage of development.
• The corporate governance practices, such as having independent directors and audit and compensation committees, align with best practices and regulatory requirements for Nasdaq-listed companies.
• Comparing TherapeuticsMD's governance structure with companies like Amarin Corporation or Adamas Pharmaceuticals would provide a more detailed assessment of its alignment with industry peers.

Corporate Governance

Related Party Transactions

• Mr. Roberts currently serves as a Partner of Rubric.
• On July 29, 2022, September 30, 2022, October 28, 2022 and May 1, 2023, we entered into subscription agreements with Rubric.
• On December 30, 2022, and in accordance with the terms of the Certificate of Designation, the Company redeemed all 29,000 outstanding shares of the Companys Series A Preferred Stock from Rubric at a purchase price of $1,333 per share.
• The Company also paid certain affiliates of Rubric approximately $3.0 million as a make-whole payment pursuant to the subscription agreements previously entered into between the Company and Rubric.
• On June 29, 2023, we issued and sold 312,525 shares of Common Stock to Rubric at a price per share equal to $3.6797 pursuant to the subscription agreement and received gross proceeds of $1.15 million before expenses.
• On November 15, 2023, Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal to $2.2761.
• We received gross proceeds of $2.0 million from the drawdown before expenses.

Stakeholder Impact

• Shareholders receive more complete information about the company's governance and executive compensation.
• Employees are subject to policies on insider trading, hedging, and pledging, ensuring fair practices.
• The company's commitment to ethical conduct and compliance with regulations enhances its reputation with customers and suppliers.

Key Dates

Keywords

corporate governance, executive compensation, directors, TherapeuticsMD, Form 10-K/A, financial reporting, stockholders, audit committee, compensation committee